Please login to the form below
BPDCN
This page shows the latest BPDCN news and features for those working in and with pharma, biotech and healthcare.
Orphan drugs dominate FDA's record-breaking year
The last few days of the year also saw approvals for Stemline Therapeutics’ Elzonris (tagraxofusp) – the first drug to be licensed for rare cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) – and
Latest news
-
Cellectis floored by patient death in CAR-T trial
The 78-year-old man with blastic plasmacytoid dendritic cell neoplasm (BPDCN) started the treatment with Cellectis' UCART123 candidate at the MD Anderson Cancer Centre in the US in mid-August ... Shares in Cellectis went into a nosedive on news of the
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Principal Medical Writer
-
Varies on experience
- Senior Content Editor - Biotechnology
-
Salary TBC
-
Account Management
-
Competitive Salary Offered
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- CureVac expands COVID-19 vaccine trial protocol to include variant specification
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Bedrock Group rebrands as Resonant Group
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Moderna launches COVID-19 vaccine booster study to address new variants
- Live Webinar: Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Opdivo improves survival in oesophageal cancer
- Keytruda shows significant and meaningfully improvement in kidney cancer
- Congress 2020 BC (before COVID-19)
- Shaping the Future of Medicine, Science, and Technology
- Live Webinar: Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
- When Will We Be Back To Normal?
- The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
- How to tell your healthcare story.
- Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....
Quick links
Infographics
